ASPHO 2019 Review Course January 31-February 2, 2019

Size: px

Start display at page:

Download "ASPHO 2019 Review Course January 31-February 2, 2019"

Shavonne Collins
5 years ago
Views:

ASPHO 2019 Review Course January 31-February 2, 2019 ABP Content Outline Topics by Date and Speaker For additional information, see the ABP Content Outline and the ABP Content Outline with Speaker

1 ASPHO 2019 Review Course January 31-February 2, 2019 ABP Content Outline Topics by Date and Speaker For additional information, see the ABP Content Outline and the ABP Content Outline with Speaker Assignments. Thursday, January 31 11:30 am-12:30 pm Principles of Treatment in Pediatric Oncology Leo Mascarenhas, MD MS A. Anti-neoplastic therapy 1. Principles of chemotherapy 2. Principles of radiation therapy 3. Cytotoxic chemotherapy, including alkylating agents, anti-metabolites, intercalating agents, DNA-breaking agents, mitotic inhibitors, and glucocorticoids B. Supportive care 1. Oncologic emergencies 2. Anti-emetic management C. Cancer predisposition 1. Genetic disorders predisposing to malignancy (All other topics in this domain will be covered by other speakers.) 12:35-1:20 pm Survivorship and Palliative Care Karen Effinger, MD B. Supportive Care 4. Pain Management 5. Palliative and end-of-life care D. Survivorship and adolescent and young adult (AYA) oncology 1. Biologic, epidemiologic, and psychosocial considerations of the AYA 3. Fertility preservation (All other topics in this domain will be covered by other speakers.) 1:25-2:35 pm Immunology and Immunodeficiency for the Hematologists-Oncologist

2 Sung-Yun Pai, MD Domain 2: Leukocytes A. Normal leukocytes: morphology, development, function 4. Lymphocytes C. Disorders of lymphocytes 1. Mononucleosis 2. Immunodeficiencies with hematologic or oncologic implications 3. Autoimmune lymphoproliferative syndrome and other immunoregulatory diseases (A1-3 and B1-5 will be covered in the Leukocytes talk by Carl Allen) E. Lymphoma 3. Lymphoproliferative disorders (Other topics in this domain will be covered by other speakers.) Domain 10: Hematopoietic Stem-Cell Transplant (HSCT) C. Complications 1. Infections D. Disease-specific indications and outcomes 2. Immunodeficiency (A, B, C1-3 and 4 will be covered by other speakers.) 2:35-3:35 pm Stem Cell Transplantation Michael A. Pulsipher, MD, PhD A. Anti-neoplastic therapy 7. Immunotherapy and adoptive cellular therapies (cover cellular therapies; Mignon will cover Immunotherapy) Domain 10: Hematopoietic Stem-Cell Transplant (HSCT) A. Principles and products 1. Collection, processing, and storage 2. Stem-cell source and dose 3. Donor selection 4. Contraindications B. Conditioning therapy 1. Autologous HSCT 2. Allogeneic HSCT C. Complications 1. Graft failure 2. Graft-versus-host disease (GVHD) 4. Non-infectious complications (C3 will be covered by Sung-Yun Pai)

3 3:40-4:40 pm Lymphoma Paul D. Harker-Murray, MD B. Acute lymphoblastic leukemia (ALL) 4. Burkitt leukemia E. Lymphoma 1. Hodgkin lymphoma 2. Non-Hodgkin lymphoma (NHL) Please include disease-specific late effects and indications and outcomes for BMT. 4:50-5:50pm Acute Lymphoblastic Leukemia Mignon Loh, MD A. Anti-neoplastic therapy 8. Immunotherapy and adoptive cellular therapies (cover Immunotherapy; Mike Pulsipher cover cellular therapies) A. General considerations: diagnostic tests 2. Imaging 3. Cerebrospinal fluid analysis 4. Immunological markers 5. Cytogenetics and molecular markers B. Acute lymphoblastic leukemia (ALL) 1. Pre-B cell 2. Infant ALL 3. T-cell 5. Bi-phenotypic leukemia 6. Sanctuary sites 7. Relapsed ALL Please include disease-specific late effects and indications and outcomes for BMT. (A1 will be covered by Mark Fleming and B4 will be covered by Paul Harker-Murray) 5:55-6:40 pm Vascular Malformations Denise Adams. MD Domain 9: Solid Tumors G. Rare tumors 3. Vascular tumors and malformation (The rest of this domain is covered in other talks) Domain 4: Hemostasis/Thrombosis C. Acquired disorders of coagulation 3. Coagulopathy associated with vascular malformations

4 (The rest of this domain is covered in other talks) Friday February 1 7:30-8:30 am Acute and Chronic Myelogenous Leukemia Patrick A. Brown, MD A. General considerations: diagnostic tests 2. Imaging 3. Cerebrospinal fluid analysis 4. Immunological markers 5. Cytogenetics and molecular markers C. Acute myelogenous leukemia (AML) 1. Myeloid leukemias 2. Promyelocytic leukemia (M3) 3. Megakaryocytic leukemia (M7) 4. Extramedullary disease 5. Relapsed AML D. Myelodysplastic syndrome (MDS) and myeloproliferative disorders 2. Myeloproliferative neoplasms (MPN), including CML Please include disease-specific late effects and indications and outcomes for BMT. (A1 will be covered by Mark Fleming and Myeloproliferative neoplasms (MPN), including JMML will be covered by Ken McClain) 8:35-9:35am Myeloproliferative, Myelodysplastic, and Histiocytic Disorders Ken McClain, MD D. Myelodysplastic syndrome (MDS) and myeloproliferative disorders 1. MDS 2. Myeloproliferative neoplasms (MPN), including JMML 3. Transient abnormal myelopoiesis (TAM) (All other topics in this domain will be presented by other speakers. Pat Brown will address Myeloproliferative neoplasms (MPN), including CML ) Please include Disease-specific late effects and indications and outcomes for BMT. 9:55-10:55am Sarcomas David O. Walterhouse, MD Domain 9: Solid Tumors A. General considerations 1. Clinical presentations 2. Diagnostic imaging 3. Pathology 4. Other laboratory tests

5 B. Sarcomas 1. Osteosarcoma 2. Ewing sarcoma and Ewing family of tumors 3. Rhabdomyosarcoma 4. Non-rhabdomyosarcoma soft-tissue sarcomas Please include Disease-specific late effects and indications and outcomes for BMT. 11:00-12:00pm Retinoblastoma, Germ Cell Tumors, and Hepatoblastoma Carlos Rodriguez-Galindo, MD Domain 9: Solid Tumors A. General considerations 1. Clinical presentations 2. Diagnostic imaging 3. Pathology 4. Other laboratory tests E. Liver tumors 1. Hepatoblastoma 2. Hepatocellular carcinoma G. Rare tumors 1. Germ-cell tumors 2. Retinoblastoma 4. Other rare tumors in childhood and adolescence Please include Disease-specific late effects and indications and outcomes for BMT (G3 and all other topics in this domain will be presented by other speakers.) 12:40 1:25 pm Review of Peripheral Blood and Bone Marrow Morphology: Malignant Diseases Mark Fleming, MD A. General considerations: diagnostic tests 1. Peripheral blood smears and bone marrow aspirate/biopsy 1:30-2:30 pm Brain Tumors Jason Fangusaro, MD Domain 9: Solid Tumors A. General considerations 1. Clinical presentations 2. Diagnostic imaging 3. Pathology 4. Other laboratory tests F. Brain tumors 1. Medulloblastoma 2. Low-grade glioma 3. High-grade glioma

6 4. Ependymoma 5. Central nervous system germ-cell tumors 6. Rare brain tumors Please include disease-specific late effects and indications and outcomes for BMT. 2:35-3:35pm Neuroblastoma and Wilms' Tumor Julie R. Park, MD A. Anti-neoplastic therapy 10. Radioisotope therapy Domain 9: Solid Tumors A. General considerations 1. Clinical presentations 2. Diagnostic imaging 3. Pathology 4. Other laboratory tests C. Neuroblastoma and related tumors 1. Neuroblastoma 2. Ganglioneuroma 3. Paraganglioma/pheochromocytoma D. Renal tumors 1. Wilms tumor 2. Other primary renal tumors Please include disease-specific late effects and indications and outcomes for BMT. 3:55-4:55 pm Bone Marrow Failure Zora Rogers, MD Domain 5: Bone Marrow Failure A. Hematopoiesis 1. Normal hematopoiesis 2. Abnormal hematopoiesis 3. Approaches to pancytopenia B. Acquired bone marrow failure 1. Idiopathic aplastic anemia 2. Secondary marrow suppression C. Inherited bone marrow failure 1. Fanconi anemia 2. Dyskeratosis congénita 3. Shwachman-Diamond síndrome 4. Congenital neutropenia 5. Diamond-Blackfan anemia 6. Congenital thrombocytopenia 7. Other inherited bone marrow failure syndromes

7 Please include disease-specific late effects and indications and outcomes for BMT. 5:00-6:15 pm Transfusion Medicine Rowena Punzalan Domain 6: Transfusion Medicine A. Collection and storage characteristics 1. Erythrocytes 2. Platelets 3. Granulocytes 4. Plasma and cryoprecipitate B. Typing and crossmatching for transfusion 1. Erythrocytes 2. Platelets C. Indications for and administration of transfusion 1. Erythrocytes 2. Platelets 3. Granulocytes 4. Plasma and cryoprecipitate 5. Therapeutic apheresis 6. Directed donors D. Attributes/special processing 1. Irradiation Leukoreduction 3. Plasma reduction E. Complications of blood and blood product transfusions 1. Transfusion-transmitted disease 2. Transfusion reactions 3. Rh-incompatible transfusion Saturday, February 2 7:30-8:30 am Nutritional Anemias Matthew M. Heeney, MD Domain 1: Erythrocytes A. The erythron 1. Developmental changes of the erythron 2. Normal erythrocytes 3. Erythrocyte physiology 4. Approach to anemia F. Iron disorders 1. Iron deficiency anemia 2. Anemia of chronic disease and disorders of iron metabolism 3. Congenital iron overload

8 G. Megaloblastic anemia 1. Nutritional deficiencies: folate and B12 2. Metabolic disorders and drugs H. Erythrocytosis 1. Primary or secondary 8:35-9:35 am Congenital and Acquired Hemolytic Anemias Rachael Grace, MD Domain 1: Erythrocytes B. Hemolytic anemias 1. General features 2. Antibody/complement-mediated 3. Membrane/cytoskeleton/ion channel 4. Enzymopathies 5. Unstable hemoglobin 6. Fragmentation 9:55-10:55 am Hemoglobinopathies Melissa Frei-Jones, MD Domain 1: Erythrocytes C. Hemoglobin S and sickling syndromes 1. General features of sickle cell anemia (HbSS), sickle-hemoglobin C disease (HbSC), sickle-β thalassemia, and sickle cell trait 2. Central nervous system complications 3. Other acute complications 4. Chronic complications 5. Treatment, including supportive care 6. Transfusional iron overload D. Other disorders of hemoglobin 1. Hemoglobin E 2. Other hemoglobin disorders e.g. methemoglobinemia E. Thalassemia syndromes 1. General features 2. α-thalassemia 3. β-thalassemia 11:00 am-12:00 pm Disorders of Leukocytes Carl Allen, MD, PhD Domain 2: Leukocytes A. Normal leukocytes: morphology, development, function

9 1. Neutrophils 2. Eosinophils/basophils/mast cells 3. Monocytes/macrophages/dendritic cells B. Disorders of granulocytes 1. Acquired neutropenia 2. Morphologic abnormalities 3. Neutrophilia 4. Neutrophil dysfunction 5. Eosinophilia D. Disorders of the reticuloendothelial system 1. Splenomegaly 2. Hemophagocytic lymphohistiocytosis (HLH) F. Histiocytic neoplasms 1. Langerhans cell histiocytosis (LCH) (All other topics in these domains will be presented by other speakers.) 12:40-1:25 pm Review of Peripheral Blood and Bone Marrow Morphology: Non-malignant Matt Oberley, MD, PhD 1:30-2:30 pm Blood Coagulation Overview and Acquired Hemorrhagic Disorders Guy Young, MD Domain 4: Hemostasis/Thrombosis A. Normal physiology of coagulation factors and vessel wall 1. Procoagulant factors 2. Anticoagulant factors 3. Fibrinolytic system 4. Role of vessel wall in regulation of hemostasis C. Acquired disorders of coagulation 1. Disseminated intravascular coagulation (DIC), vitamin K deficiency, and liver disease 3. Coagulopathy associated with vascular malformations 4. Other acquired coagulopathies (C2 will be covered by Sarah O Brien) 2:35-3:35 pm Inherited Coagulation Disorders Guy Young, MD Domain 4: Hemostasis/Thrombosis B. Inherited disorders of coagulation 1. Approach to bleeding 2. Congenital Factor VIII and Factor IX deficiency 3. von Willebrand disease 4. Abnormalities of other proteins, circulating and vascular (D will be covered by Sarah O Brien)

10 3:35-4:55 pm Thrombotic Disorders Sarah O Brien, MD Domain 4: Hemostasis/Thrombosis C. Acquired disorders of coagulation 2. Lupus anticoagulants and coagulation inhibitors D. Thrombotic disorders 1. Approach to thrombosis 2. Inherited thrombophilia 3. Acquired risk factors for thrombosis 4. Anticoagulation: unfractionated heparin, low molecular-weight heparin, vitamin K antagonists, direct thrombin inhibitors, and other anticoagulants 5. Thrombolysis 6. Post-thrombotic syndrome 5:00-6:00 pm Platelet Disorders Cindy E. Neunert Domain 3: Platelets A. Normal physiology of platelets 1. Platelet production, kinetics, and function 2. Thrombocytopenia: general considerations B. Disorders of platelet number and function 1. Thrombocytopenia in the newborn period 2. Immune thrombocytopenia 3. Other acquired thrombocytopenic states 4. Inherited disorders of platelet function and/or number 5. Acquired disorders of platelet function 6. Thrombocytosis Online Presentations Michael Anderson, PhD Domain 11: Core Knowledge in Scholarly Activities A. Principles of biostatistics in research 1. Types of variables 2. Distribution of data 3. Hypothesis testing 4. Common statistical tests 5. Measurement of association and effect 6. Regression 7. Diagnostic tests 8. Systematic review and meta-analysis B. Principles of epidemiology and clinical research design

11 1. Study design, performance, and analysis (internal validity) 2. Generalizability (external validity) 3. Bias and confounding 4. Causation 5. Incidence and prevalence 6. Screening 7. Cost benefit, cost effectiveness, and outcomes 8. Measurement (All other topics in this domain will be cover by other speakers.) Jennifer Kesselheim, MD Med Domain 11: Core Knowledge in Scholarly Activities C. Ethics in research 1. Professionalism and misconduct in research 2. Principles of research involving human subjects 3. Principles of consent and assent D. Quality improvement 1. Project design 2. Data and measurement (All other topics in this domain will be cover by other speakers.) Jenny Moran A. Anti-neoplastic therapy 4. Differentiating agents 5. Targeted therapies 6. Epigenetic modifiers 8. Immune checkpoint inhibitors 9. Anti-angiogenic agents (All other topics in this domain will be cover by other speakers.)

Pediatric Hematology-Oncology

Pediatric Hematology-Oncology Content Outline In-Training, Initial Certification, and Maintenance of Certification Exams Effective for exams administered beginning April 1, 2019 THE AMERICAN BOARD of PEDIATRICS